In this study, inactivation of p110δ in p110δ-high CRPC cells suppressed PI3K-AKT signaling and inhibited cell proliferation, suggesting p110δ inhibitors may prove to hold therapeutic efficacy against p110δ-high prostate cancer [58]. Here, PIK3CG is linked to prostate carcinoma.